Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Capable of complying with the study procedures.~* Able to provide written informed consent~* Male or female aged 18 to 65 years, inclusive.~* Diagnosis of partial onset seizures~* Minimum of three seizures per 28 days~* Receiving treatment with 1-3 AEDs~* Refractory to at least one AED~* No progressive neurological conditions by recent MRI/CT~* Adequate birth control in women of child-bearing potential~Exclusion Criteria:~* Refractory to OXC for reasons of efficacy~* Recent status epilepticus~* Recent non-epileptic seizures~* Current diagnosis of major depression~* Recent suicidal plan or intent or more than one attempt~* Current use of oxcarbazepine, felbamate for \< 18 months, phenytoin with levels \>15mcg/mL or frequent need for rescue benzodiazepines~* Current use of sodium-lowering non-seizure medications.~* Clinically significant hepatic, renal, or cardiovascular function~* History of recent substance abuse~* Females who are pregnant or lactating.~* Hypersensitivity to OXC or related drugs~* Difficulty swallowing study medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo - four identical tablets taken orally once daily
- 2400 mg SPN-804 (Type: ACTIVE_COMPARATOR): 2400mg OXC XR taken orally once daily as four identical tablets
- 1200mg SPN-804 (Type: ACTIVE_COMPARATOR): 1200mg OXC XR taken orally once daily as four identical tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).